课题基金 / 基金详情

Experimental Therapeutics Program

Experimental Therapeutics Program
实验治疗计划
批准号:
10362645
负责人:
ALEX A. ADJEI
金额:
$9.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-04-25 至 2024-02-29
关键词:
AddressAdjuvantAffectAgingAllelesAntineoplastic AgentsApoptoticAreaAromatase InhibitorsBCL2 geneBRCA1 ProteinBRCA1 geneBRCA2 geneBasic ScienceBindingBiochemicalBiochemical GeneticsBioinformaticsBiologicalBiometryBreast Cancer CellBreast cancer metastasisCDK4 geneCell ProliferationCell SurvivalCellsChemopreventive AgentClinicClinicalClinical ResearchClinical TrialsCollaborationsCombination immunotherapyComprehensive Cancer CenterDNADNA DamageDNA RepairDNA Repair PathwayDiseaseDoctor of PhilosophyDrug KineticsERBB2 geneErinaceidaeEstrogen ReceptorsEvaluable DiseaseFamily memberFloxuridineFundingFutureGeneticGenomicsGoalsGrantHandHematopoieticHormonalImmunologicsImmunooncologyIn SituIndividual DifferencesInvestigationInvestigational TherapiesJointsJournalsLung AdenocarcinomaMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of ovaryMalignant neoplasm of pancreasMayo Clinic Cancer CenterMentorshipMetabolicMicroscopyMutationNOTCH3 geneOncogenicOrganOvarianPathologyPathway interactionsPatientsPeer ReviewPharmacogeneticsPharmacologyPharmacy facilityPhosphotransferasesPlatinumPreclinical Drug DevelopmentPropertyProtein KinaseProteomicsProteomics Shared ResourcePublicationsPublishingReagentResearchResearch PersonnelResistanceResource SharingResourcesRunningSafetySamplingSelective Estrogen Receptor ModulatorsSignal PathwaySignal TransductionSignal Transduction InhibitorSingle Nucleotide PolymorphismSiteSourceTamoxifenTestingToxic effectTranslational ResearchTranslationsTumor Suppressor ProteinsValidationVariantWomanWorkanticancer treatmentbasecancer cellcareerchemotherapyearly phase clinical trialearly phase trialeffective therapyepithelial to mesenchymal transitionfirst-in-humangemcitabinegenome analysisgenome wide association studyimprovedinhibitorinsightmalignant breast neoplasmmembermimeticsmitochondrial creatine kinaseneoplasticneoplastic cellnew therapeutic targetnovelnovel anticancer drugphase 2 testingphase I trialphase II trialpre-clinicalprogramsresearch clinical testingresponsesafety assessmentsmall molecule therapeuticsubiquitin isopeptidase

项目摘要

项目成果

ALEX A. ADJEI的其他基金

相似基金

相关文献

中文摘要
翻译
实验治疗学计划项目摘要 实验治疗(ET)计划有助于更有效地治疗肿瘤疾病 通过一系列基础研究和翻译研究。其目的是:1)定义参与的细胞通路 生存和增殖,以便更好地了解对现有治疗的反应并确定 新的治疗靶点;2)阐明其作用的生物学、生化和药理学方面 新的抗癌药物和鉴定有助于肿瘤细胞耐药的生化特性; 3)评估潜在的基因和基因组对抗癌治疗的疗效和毒性的贡献;以及 4)在本计划和其他研究的基础上,进行早期临床试验,并移交给疾病- 在安全性、药代动力学、 临床环境中的药物遗传学和生物效应。该计划由楼振坤联合领导, Scott Kaufmann,医学博士和Alex Adjei,医学博士,博士,他们在DNA修复,细胞 信号、细胞药理学和早期临床试验的进行。ET计划有46个 来自13个部门和司的成员,直接资金总额为1260万美元(800万美元,经同行审查,占88% 来自NCI)。自上次竞争续订以来,该计划已出版了777份出版物(129份出版于 影响因子为≥10的期刊,影响因子为≥20的期刊),其中21%和50%的出版物反映了 分别是方案内和方案间协作。值得注意的成就包括1) 蛋白激酶Cι通过Hedgehog途径转化肺腺癌的研究 通过河马/YAP途径发生的卵巢癌;2)临床前研究表明CDK4/6抑制剂改变 乳腺癌细胞上皮向间充质转化和转移导致CDK4/6 妇女癌症计划中的抑制剂/芳香酶抑制剂II期试验;3)证明ZNF423 调节BRCA1的表达,这一途径中的等位基因变异影响着肿瘤的化学预防效果 他莫昔芬;4)完成了Enoxifen和PARP抑制剂的I期试验,并启动了早期 ATR抑制剂的阶段试验。该计划广泛利用共享资源,特别是 显微镜和细胞分析、蛋白质组学、病理学研究、基因组分析、药理学和 药房设施以及临床研究办公室。该计划为梅奥癌症诊所增加了价值 通过I中心(MCCC)将研究人员聚集在一起,共同强调临床前和早期临床 小分子疗法的研究,单独或与免疫肿瘤学药物联合使用,以及ii)用作 MCCC计划早期临床试验的资源。该计划的未来目标包括1)进一步 脱泛素酶及其抑制剂作为DNA修复途径调节剂的临床前工作,2)扩增 我们对癌症代谢靶点的重视,以及3)正在进行的DNA修复、代谢工作的翻译 目标和化疗/免疫疗法的组合纳入新的临床试验。
英文摘要
EXPERIMENTAL THERAPEUTICS PROGRAM PROJECT SUMMARY The Experimental Therapeutics (ET) Program contributes to more effective treatment of neoplastic diseases through a spectrum of basic and translational research. The Aims are to 1) define cellular pathways involved in survival and proliferation in order to improve understanding of response to established treatments and identify new therapeutic targets; 2) elucidate biological, biochemical, and pharmacological aspects of the action of novel anti-cancer agents and identify biochemical properties that contribute to tumor cell resistance; 3) evaluate potential genetic and genomic contributions to efficacy and toxicity of anticancer treatments; and 4) conduct early phase clinical trials, based on research in this Program and others, with hand off to disease- specific clinical Programs for phase II testing after initial assessment of safety, pharmacokinetics, pharmacogenetics, and biological effects in the clinical setting. The Program is jointly led by Zhenkun Lou, PhD, Scott Kaufmann, MD, PhD, and Alex Adjei, MD, PhD, who have expertise in DNA repair, cellular signaling, cellular pharmacology, and the conduct of early phase clinical trials. The ET Program has 46 members from 13 departments and divisions, with total direct funding of $12.6M ($8M peer-reviewed, with 88% from NCI). Since the last competitive renewal, the Program has generated 777 publications (129 published in journals with impact factor ≥10, 42 with impact factor ≥20) with 21% and 50% of these publications reflecting intra- and interprogrammatic collaborations, respectively. Notable accomplishments include 1) the demonstration that protein kinase Cι transforms lung adenocarcinoma through the hedgehog pathway and ovarian cancer through the Hippo/YAP pathway; 2) preclinical work showing that CDK4/6 inhibitors alter the epithelial-to-mesenchymal transition and metastasis of breast cancer cells, leading to a CDK4/6 inhibitor/aromatase inhibitor phase II trial in the Women's Cancer Program; 3) demonstration that ZNF423 regulates BRCA1 expression, and allelic variation in this pathway affects the chemopreventive efficacy of tamoxifen; and 4) completion of phase I trials of endoxifen and PARP inhibitors as well as initiation of early phase trials of ATR inhibitors. The Program makes extensive use of Shared Resources, especially the Microscopy and Cell Analysis, Proteomics, Pathology Research, Genome Analysis, Pharmacology, and Pharmacy facilities as well as the Clinical Research Office. The Program adds value to the Mayo Clinic Cancer Center (MCCC) by i) bringing together investigators with a shared emphasis on the preclinical and early clinical study of small molecule therapeutics, alone or in conjunction with immuno-oncology agents, and ii) serving as a resource for early phase clinical trials for MCCC Programs. Future goals of the program include 1) further preclinical work on deubiquitinases and their inhibitors as modulators of DNA repair pathways, 2) expansion of our emphasis on metabolic targets in cancer, and 3) translation of ongoing work on DNA repair, metabolic targets, and chemotherapy/immunotherapy combinations into novel clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors
  • 批准号:
    9815079
  • 项目类别:
  • 资助金额:
    $10.8万
  • 财政年份:
    2018
  • 负责人:
    ALEX A. ADJEI
  • 依托单位:
Phase 2 Clinical Trials Program for Experimental Therapeutics Clinical Trials Network
  • 批准号:
    9094959
  • 项目类别:
  • 资助金额:
    $91.25万
  • 财政年份:
    2014
  • 负责人:
    ALEX A. ADJEI
  • 依托单位:
Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
  • 批准号:
    9086290
  • 项目类别:
  • 资助金额:
    $71.82万
  • 财政年份:
    2014
  • 负责人:
    ALEX A. ADJEI
  • 依托单位:
海外基金